Pancreatic Cancer Research

ResearcherColumbia UniversityActive in the last 2 years

Marina Macchini

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5395-0155; OpenAlex author ID A5085754158. Sources: OpenAlex.

Their work

Papers
46 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
134
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: 3 papers · 2019: 1 paper · 2020: 2 papers · 2021: 6 papers · 2022: 4 papers · 2023: 7 papers · 2024: 8 papers · 2025: 4 papers · 2026: 7 papers

Papers 46

  1. Impact of nutritional status on chemotherapy delivery and outcomes in advanced pancreatic cancer: A prospective multicenter study. Co-author DOI 10.1016/j.clnu.2025.106573↗
  2. Pancreatic adenocarcinoma nutritional-clinical index (PANCIN): A novel prognostic tool in advanced pancreatic cancer. Co-author DOI 10.1016/j.dld.2026.02.015↗
  3. A robust biomarker combining radiomic and CA19.9 information to predict distant relapse-free survival after radiochemotherapy in pancreatic cancer. Co-author DOI 10.1016/j.dld.2026.09.026↗
  4. Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results f… Co-author DOI 10.1016/j.eclinm.2026.104190↗
  5. Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.117033↗
  6. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the … First author DOI 10.1016/s0140-6736(25)01685-x↗
  7. Multimodal Prehabilitation In Pancreatic cancer Patients undergoing surgery (PIPS): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-026-09467-z↗
  8. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. Co-author DOI 10.1002/cam4.70364↗
  9. Exploring external validity of chemotherapy for pancreatic ductal adenocarcinoma in real life. Co-author DOI 10.1016/j.dld.2024.06.025↗
  10. Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. Co-author DOI 10.1016/j.dld.2025.03.009↗
  11. Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional … Co-author DOI 10.1016/j.esmoop.2024.104001↗
  12. Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ctro.2024.100778↗
  13. Exploring the optimal therapeutic management of stage ypIA pancreatic ductal adenocarcinoma patients in the era of primary chemotherapy. Co-author DOI 10.1016/j.dld.2023.07.006↗
  14. Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.dld.2023.07.033↗
  15. Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients. Co-author DOI 10.1016/j.ejca.2024.114226↗
  16. Communication, understanding and engagement of patients with pancreatic cancer at time of diagnosis. Co-author DOI 10.1016/j.pan.2024.02.008↗
  17. A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variants. Co-author DOI 10.1016/j.pan.2024.09.006↗
  18. Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence. Co-author DOI 10.1016/j.surg.2024.07.026↗
  19. Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarci… Co-author DOI 10.1186/s12885-024-12936-w↗
  20. Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer. First author DOI 10.1001/jamaoncol.2022.7358↗
  21. Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA… Co-author DOI 10.1007/s00280-023-04585-w↗
  22. The Role of Neoadjuvant FOLFIRINOX in Borderline Resectable Pancreatic Cancer: A Network Meta-Analysis. Co-author DOI 10.1007/s12029-023-00923-6↗
  23. Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Samples. Co-author DOI 10.1016/j.cgh.2022.10.014↗
  24. The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.dld.2023.04.015↗
  25. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary a… Co-author DOI 10.1016/j.esmoop.2022.100777↗
  26. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Co-author DOI 10.1038/s41416-022-02086-w↗
  27. Is the Delphi's Oracle Pertinent to Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma? First author DOI 10.1001/jamaoncol.2022.4673↗
  28. Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Co-author DOI 10.1016/j.critrevonc.2021.103571↗
  29. Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1016/j.ctrv.2022.102357↗
  30. The impact of nutritional status on pancreatic cancer therapy. Co-author DOI 10.1080/14737140.2022.2026771↗
  31. Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients. Co-author DOI 10.1007/s00280-020-04190-1↗
  32. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants. Co-author DOI 10.1016/j.ctrv.2021.102262↗
  33. Multidrug regimens for treatment of older patients with metastatic pancreatic cancer. Co-author DOI 10.1016/j.dld.2020.06.006↗
  34. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. Co-author DOI 10.1016/j.esmoop.2020.100032↗
  35. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter surve… Co-author DOI 10.1016/j.esmoop.2021.100238↗
  36. Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression. First author DOI 10.1136/gutjnl-2019-319912↗
  37. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00280-020-04047-7↗
  38. Circulating Chromogranin A Is Cleaved Into Vasoregulatory Fragments in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2020.613582↗
  39. Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives. Co-author DOI 10.1016/j.ctrv.2018.10.013↗
  40. β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.11.007↗
  41. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreati… Co-author DOI 10.1016/j.ejca.2018.07.007↗
  42. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. Co-author DOI 10.1016/s2468-1253(18)30196-1↗
  43. Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array. Co-author DOI 10.3892/mmr.2015.4344↗
  44. Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. Co-author DOI 10.1097/mpa.0b013e3182a6486e↗
  45. Hedgehog signaling: from the cuirass to the heart of pancreatic cancer. First author DOI 10.1016/j.pan.2012.06.001↗
  46. Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer: A literature review and report of two cases. First author DOI 10.3892/ol.2011.253↗

Closest collaborators

The 25 strongest of 134 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michele Reni · 38 shared papers, 2018–2026 · strength 6.31
  2. Giulia Orsi · 29 shared papers, 2020–2026 · strength 5.06
  3. Massimo Falconi · 21 shared papers, 2018–2026 · strength 3.45
  4. Umberto Peretti · 17 shared papers, 2018–2025 · strength 2.31
  5. Stefano Cascinu · 13 shared papers, 2021–2025 · strength 1.97
  6. Michèle Milella · 10 shared papers, 2021–2026 · strength 1.57
  7. Gabriele Capurso · 8 shared papers, 2022–2026 · strength 1.51
  8. Letizia Procaccio · 8 shared papers, 2023–2026 · strength 1.46
  9. Ilario Giovanni Rapposelli · 9 shared papers, 2021–2026 · strength 1.45
  10. Paolo Giorgio Arcidiacono · 9 shared papers, 2018–2026 · strength 1.44
  11. Catia Carconi · 7 shared papers, 2024–2026 · strength 1.43
  12. Domenico Tamburrino · 8 shared papers, 2020–2026 · strength 1.34
  13. Mariacristina Di Marco · 12 shared papers, 2011–2026 · strength 1.31
  14. Diego Palumbo · 6 shared papers, 2022–2026 · strength 1.26
  15. Silvia Bozzarelli · 7 shared papers, 2021–2026 · strength 1.13
  16. Giulio Belfiori · 6 shared papers, 2021–2026 · strength 1.05
  17. Nicolò Pecorelli · 5 shared papers, 2022–2026 · strength 1.05
  18. Mario Scartozzi · 6 shared papers, 2021–2026 · strength 0.98
  19. Guido Giordano · 7 shared papers, 2021–2025 · strength 0.95
  20. Giampaolo Tortora · 7 shared papers, 2021–2025 · strength 0.92
  21. Lívia Archibugi · 5 shared papers, 2023–2026 · strength 0.92
  22. Stefano Crippa · 5 shared papers, 2022–2026 · strength 0.90
  23. Sara Lonardi · 5 shared papers, 2023–2026 · strength 0.90
  24. Giovanni Guarneri · 4 shared papers, 2025–2026 · strength 0.88
  25. Stefano Partelli · 5 shared papers, 2018–2026 · strength 0.84

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.